Designing Studies for Epigenetic Biomarker Development in Autoimmune Rheumatic Diseases

Rheumatol Immunol Res. 2022 Oct 20;3(3):103-110. doi: 10.2478/rir-2022-0018. eCollection 2022 Oct.

Abstract

In just a few years, the number of epigenetic studies in autoimmune rheumatic and inflammatory diseases has greatly increased. This is in part due to the need of identifying additional determinants to genetics to explain the pathogenesis and development of these disorders. In this regard, epigenetics provides potential mechanisms that determine gene function, are linked to environmental factors, and could explain a wide range of phenotypic variability among patients with these diseases. Despite the high interest and number of studies describing epigenetic alterations under these conditions and exploring their relationship to various clinical aspects, few of the proposed biomarkers have yet reached clinical practice. The potential of epigenetic markers is high, as these alterations link measurable features with a number of biological traits. In the present article, we present published studies in the field, discuss some frequent limitations in the existing research, and propose a number of considerations that should be taken into account by those starting new projects in the field, with an aim to generate biomarkers that could make it into the clinics.

Keywords: autoimmune diseases; biomarkers; epigenetics; inflammation; rheumatic diseases.

Publication types

  • Review